John Weiland
About John H. Weiland
Independent director at Solventum since 2024; age 69. Former President and COO of C. R. Bard (2003–2017) and Bard board member (2005–2017; Vice Chair in 2016). Earlier roles at Dentsply International, American Hospital Supply, Baxter Healthcare, and Pharmacia AB. Brings deep healthcare manufacturing, regulatory, and operational expertise; currently chairs Solventum’s Science, Technology & Quality Committee (STQ) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| C. R. Bard, Inc. | President & COO; Director (Vice Chair in 2016) | 2003–2017 (COO/President); 2005–2017 (Director) | Oversaw workflow optimization and cost reduction driving significant growth; senior responsibility for worldwide manufacturing . |
| C. R. Bard, Inc. | Group President | 1996–2003 | Global responsibility for multiple divisions and manufacturing . |
| Dentsply International | Senior management | 1991–1996 | North America senior leadership . |
| American Hospital Supply; Baxter Healthcare; Pharmacia AB | Senior roles | n/a | Healthcare operations and commercial leadership experience . |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Cardinal Health, Inc. | Director | 2019–2022 | Chaired Risk Oversight Committee . |
| Celgene Corporation | Director | n/a | Audit Committee member . |
| West Pharmaceutical Services | Director | n/a | Chaired Compensation and Finance Committees . |
| C. R. Bard, Inc. | Director | 2005–2017 | Vice Chair in 2016 . |
Board Governance
- Committee assignments (2024): Chair, Science, Technology & Quality (members: Carrie Cox, Bernard Harris Jr., Elizabeth Mily, Amy Wendell). STQ held 3 meetings in 2024 .
- Board meetings and attendance: Board met 7 times in 2024; standing committees met 18 times; all directors attended at least 75% of their board/committee meetings .
- Independence: The Board determined all directors other than the CEO are independent under NYSE standards and company guidelines; Weiland is independent .
- Board leadership and executive sessions: Independent Board Chair (Carrie S. Cox); independent directors meet privately at each regularly scheduled meeting, and may meet without CEO any time .
- Tenure on SOLV board: Director since 2024 .
Fixed Compensation
| Component | Policy / Amount | 2024 Actual for Weiland |
|---|---|---|
| Annual cash retainer (non-employee director) | $120,000 | $101,250 fees earned/paid in cash (prorated from April 1, 2024; includes STQ Chair fee) . |
| Committee Chair fee – STQ | $15,000 | Included in 2024 cash above . |
| Board Chair cash premium | $50,000 (not applicable to Weiland) | n/a . |
| Meeting fees | Not disclosed (no per-meeting fee listed) | n/a . |
Notes: Director appointments effective dates in 2024 were prorated for cash compensation; most non-employee directors (including Weiland) were effective April 1, 2024 .
Performance Compensation
| Equity Element | Grant Value / Structure | Vesting | 2024 Weiland Amount |
|---|---|---|---|
| Annual RSU grant (non-employee director) | $225,000 grant date fair value | One-year vesting | Included in $350,000 total stock awards . |
| One-time “Founder’s” RSU grant (spin-off) | $125,000 grant date fair value | Two-year cliff vest | Included in $350,000 total stock awards . |
| Total 2024 stock awards (director table) | n/a | n/a | $350,000 for Weiland . |
| Unvested RSUs outstanding (12/31/24) | n/a | n/a | 5,544 unvested RSUs for each non-employee director other than Board Chair (includes Weiland) . |
Policy protections: Directors are subject to anti-hedging and anti-pledging policies; no short sales, margin accounts, or pledging SOLV stock allowed .
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company directorships | None disclosed for Weiland in the 2025 proxy (prior directorships listed below) . |
| Prior public boards | Cardinal Health (Risk Oversight Chair); Celgene (Audit); West Pharmaceutical (Compensation & Finance Chair); C. R. Bard (Vice Chair) . |
| Compensation committee interlocks | No historical interlocks disclosed for SOLV in 2023 (pre-spin; 3M set comp) . |
Expertise & Qualifications
- Healthcare manufacturing and regulatory compliance expertise; operational efficiency and supply chain optimization; global operations; strategy & M&A; risk oversight. Chair of STQ Committee underscores domain depth in science, technology, quality, and product regulatory oversight .
- Described as providing international healthcare business experience with a track record of driving growth through workflow optimization and cost reduction at Bard .
Equity Ownership
| Holder | Total Shares Beneficially Owned (3/5/2025) | Shares Acquirable in 60 Days | Percent of Class | Notes |
|---|---|---|---|---|
| John H. Weiland | — (not separately reported; <1%) | — | * (<1%) | As of 3/5/2025, based on 173,002,926 shares outstanding . |
| Unvested RSUs (12/31/2024) | 5,544 RSUs (non-employee directors other than Chair) | n/a | n/a | Includes Weiland; vesting per schedules above . |
| Ownership guidelines | Non-executive directors: 5x annual retainer (i.e., 5×$120k) | n/a | n/a | Anti-hedging/anti-pledging in effect . |
Governance Assessment
-
Strengths
- Independent director with deep medtech operating pedigree; chairs STQ Committee, central to product quality/regulatory risk—material for a diversified healthcare manufacturer .
- Board practices feature independent chair, regular executive sessions, majority voting, director independence under NYSE standards, and limits on outside boards—supporting board effectiveness .
- Director equity paid largely in RSUs with defined vesting; stock ownership guideline of 5× retainer aligns incentives; hedging/pledging prohibited—reduces misalignment risk .
-
Risks/Red Flags
- Beneficial share ownership for Weiland not separately reported (appears de minimis as of record date); while RSUs create alignment, low disclosed ownership may be viewed as modest “skin-in-the-game” in early tenure .
- Related-party controls and spin-related commercial ties (ongoing agreements with 3M) exist at company level; no Weiland-specific related-party transactions disclosed .
-
Attendance and engagement
- All directors met the minimum attendance threshold (≥75%) in 2024; committee he chairs met three times—engagement appears active during spin/build-out year .
-
Overall view
- Governance posture is shareholder-friendly with robust independence and risk oversight. Weiland’s STQ chair role is a positive signal for product/regulatory oversight; absence of conflicts and adherence to anti-hedging/pledging policies support investor confidence .
No Weiland-specific related-party transactions, hedging, or pledging were disclosed. Director equity and policy framework emphasize long-term alignment, though personal beneficial ownership appears minimal at this early stage of service .